SG11201510701QA - Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers - Google Patents

Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers

Info

Publication number
SG11201510701QA
SG11201510701QA SG11201510701QA SG11201510701QA SG11201510701QA SG 11201510701Q A SG11201510701Q A SG 11201510701QA SG 11201510701Q A SG11201510701Q A SG 11201510701QA SG 11201510701Q A SG11201510701Q A SG 11201510701QA SG 11201510701Q A SG11201510701Q A SG 11201510701QA
Authority
SG
Singapore
Prior art keywords
biomarkers
cognitive dysfunction
detecting
diseases
disease
Prior art date
Application number
SG11201510701QA
Inventor
Kazuhiko Uchida
Kohji Meno
Hideaki Suzuki
Yoshinori Nishimura
Original Assignee
Mcbi Inc
Univ Tsukuba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcbi Inc, Univ Tsukuba filed Critical Mcbi Inc
Publication of SG11201510701QA publication Critical patent/SG11201510701QA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10Complex mathematical operations
    • G06F17/18Complex mathematical operations for evaluating statistical data, e.g. average values, frequency distributions, probability functions, regression analysis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775Apolipopeptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433Serine endopeptidases (3.4.21)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Data Mining & Analysis (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Mathematical Analysis (AREA)
  • Mathematical Physics (AREA)
  • Pure & Applied Mathematics (AREA)
  • Mathematical Optimization (AREA)
  • Wood Science & Technology (AREA)
  • Computational Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Databases & Information Systems (AREA)
SG11201510701QA 2013-06-28 2013-06-28 Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers SG11201510701QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2013/067785 WO2014207888A1 (en) 2013-06-28 2013-06-28 Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers

Publications (1)

Publication Number Publication Date
SG11201510701QA true SG11201510701QA (en) 2016-01-28

Family

ID=52141287

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201510701QA SG11201510701QA (en) 2013-06-28 2013-06-28 Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers

Country Status (9)

Country Link
US (3) US20160178642A1 (en)
EP (1) EP3015865B1 (en)
JP (1) JP6265507B2 (en)
KR (1) KR101850827B1 (en)
CN (2) CN111426848A (en)
CA (1) CA2916861A1 (en)
PH (1) PH12015502849B1 (en)
SG (1) SG11201510701QA (en)
WO (1) WO2014207888A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109791139A (en) * 2016-08-09 2019-05-21 大塚制药株式会社 Use the aided diagnosis method for the Alzheimer that urine biology marks
CN106645755B (en) * 2016-12-30 2018-09-25 深圳大学 A kind of AD biomarkers and its detection method
WO2019012671A1 (en) * 2017-07-13 2019-01-17 株式会社Mcbi Biomarker for cognitive impairment disorders and detection method for cognitive impairment disorders using said biomarker
JPWO2019013341A1 (en) * 2017-07-14 2020-07-09 株式会社Mcbi Disease detection method
JP2019020206A (en) * 2017-07-14 2019-02-07 株式会社島津製作所 Cognitive disorder biomarker quantification method using mass analysis and mass spectroscope
JP7109441B2 (en) * 2017-07-25 2022-07-29 亨 長谷川 Diagnostic aid method for determining neurodegenerative disease
CN107389956B (en) * 2017-08-31 2019-05-07 北京臻惠康生物科技有限公司 New application and its kit of the transthyretin as TBI patient injury's Severity
JP7434678B2 (en) * 2019-05-20 2024-02-21 花王株式会社 Testing methods for dementia or its risk
JP7471834B2 (en) * 2020-01-24 2024-04-22 シスメックス株式会社 Method for obtaining information regarding cognitive function, method for determining effectiveness of medical intervention regarding cognitive function, method for assisting in the determination of cognitive function, reagent kit, determination device, and computer program
WO2022102654A1 (en) * 2020-11-10 2022-05-19 株式会社Mcbi Combination of biomarkers, and method for detecting cognitive dysfunction or risk thereof by using said combination
WO2022125415A1 (en) * 2020-12-07 2022-06-16 President And Fellows Of Harvard College Scg2 neuropeptides and uses thereof
WO2022145074A1 (en) 2020-12-28 2022-07-07 株式会社Mcbi Judgment supporting information generating method, judgment supporting information generating system, and information processing device
CN113684272A (en) * 2021-09-08 2021-11-23 百世诺(北京)医学检验实验室有限公司 Myocardial amyloidosis detection kit based on mutated TTR gene
WO2024004944A1 (en) * 2022-06-28 2024-01-04 株式会社Mcbi Assessment-supporting information generating method, assessment-supporting information generating system, and information processing device

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058052A2 (en) * 2002-12-20 2004-07-15 Applera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
JP4170139B2 (en) 2003-05-07 2008-10-22 財団法人癌研究会 Method for detecting change in serum apolipoprotein A-II amount
JP4801930B2 (en) 2005-05-02 2011-10-26 株式会社Mcbi Novel liver cancer biomarker and method for detecting liver cancer using the biomarker
GB2428240A (en) * 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
US7851172B2 (en) * 2006-07-25 2010-12-14 University Of Kentucky Research Foundation Biomarkers of mild cognitive impairment and alzheimer's disease
JP2010271078A (en) 2009-05-19 2010-12-02 Mcbi:Kk Biomarker of mental disorder containing cognitive disorder, and method of detecting mental disorder containing cognitive disorder using biomarker
JP2012037349A (en) 2010-08-06 2012-02-23 Mcbi:Kk Biomarker of cognitive function disorder disease and method for detecting cognitive function disorder disease using the biomarker
JP6012923B2 (en) * 2010-12-22 2016-10-25 株式会社Mcbi Biomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using the biomarker
WO2012149607A1 (en) * 2011-05-03 2012-11-08 Commonwealth Scientific And Industrial Research Organisation Method for detection of a neurological disease
FI20115576A0 (en) * 2011-06-10 2011-06-10 Teknologian Tutkimuskeskus Vtt Oy A method for diagnosing Alzheimer's disease

Also Published As

Publication number Publication date
US20200309789A1 (en) 2020-10-01
CA2916861A1 (en) 2014-12-31
KR101850827B1 (en) 2018-05-31
PH12015502849A1 (en) 2016-03-21
JPWO2014207888A1 (en) 2017-02-23
EP3015865A4 (en) 2017-06-07
EP3015865A1 (en) 2016-05-04
JP6265507B2 (en) 2018-01-24
CN111426848A (en) 2020-07-17
CN105659093A (en) 2016-06-08
PH12015502849B1 (en) 2016-03-21
EP3015865B1 (en) 2020-03-25
WO2014207888A1 (en) 2014-12-31
US20240003913A1 (en) 2024-01-04
US20160178642A1 (en) 2016-06-23
KR20160055780A (en) 2016-05-18

Similar Documents

Publication Publication Date Title
SG11201510701QA (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
IL245935A0 (en) Methods for rna analysis
IL244627B (en) Image analysis techniques for diagnosing diseases
HK1209800A1 (en) Method and kit for non-invasively detecting egfr gene mutaions egfr
HK1220765A1 (en) Method of imaging a sample
ZA201504861B (en) Apparatus for improved disease detection
GB201318824D0 (en) Tyre condition analysis
EP2994044A4 (en) Analysis and detection for arhythmia drivers
GB201319779D0 (en) Genetic analysis method
EP2971285A4 (en) Blood biomarkers that predict persistent cognitive dysfunction after concussion
EP2997363A4 (en) Apparatus and methods for cellular analysis
EP3003125A4 (en) System and method for detecting neurological disease
EP2657706A4 (en) Biomarker for cognitive dysfunction diseases, and method for detection of cognitive dysfunction diseases using the biomarker
ZA201604038B (en) Improved method for rapid analysis of gold
IL244042B (en) Method for the treatment of fibrotic disease
IL240346A0 (en) Means and methods for assessing the quality of a biological sample
EP2954961A4 (en) Press-forming analysis method
PL3071969T3 (en) Method of analysis
IL250402A0 (en) Method for detecting sickle-cell disease and kit for implementing same
GB201303906D0 (en) Assay method
HK1218124A1 (en) Methods of using anti-lgr5 antibodies lgr5
IL240882B (en) Method for assessing activity of an autoinflammatory disease
HK1215073A1 (en) Methods for evaluating gemstone shape
GB201315532D0 (en) Methods for detecting proteins
GB201316131D0 (en) Biomarkers for disease stratification